Cision Newshttps://news.cision.com/seCision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.Tue, 09 Jun 2026 17:15:26 GMTCision News14660https://news.cision.com/sehttps://news.cision.com/Content/img/news-logo.pngElecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfoliohttps://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385cision5379401Mon, 08 Jun 2026 20:21:48 GMTUltomiris demonstrated 43.4% reduction in proteinuria vs placebo in adults with immunoglobulin A nephropathy at 34 weeks in I CAN Phase III trialhttps://news.cision.com/se/astrazeneca/r/ultomiris-demonstrated-43-4--reduction-in-proteinuria-vs-placebo-in-adults-with-immunoglobulin-a-nep,c4358692cision5378573Sat, 06 Jun 2026 08:35:11 GMTCamizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 mutation in SERENA-6 trialhttps://news.cision.com/se/astrazeneca/r/camizestrant-combination-delayed-time-to-first-progression-by-55--and-to-second-progression-by-37--i,c4356591cision5375492Tue, 02 Jun 2026 12:06:40 GMTImfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trialhttps://news.cision.com/se/astrazeneca/r/imfinzi-plus-imjudo-combined-with-lenvatinib-and-tace-reduced-the-risk-of-disease-progression-or-dea,c4355863cision5374542Mon, 01 Jun 2026 12:11:08 GMTCARES Phase III clinical programme did not meet primary endpoint in overall AL amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa AL amyloidosishttps://news.cision.com/se/astrazeneca/r/cares-phase-iii-clinical-programme-did-not-meet-primary-endpoint-in-overall-al-amyloidosis-populatio,c4355152cision5373456Fri, 29 May 2026 12:08:08 GMTImfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancerhttps://news.cision.com/se/astrazeneca/r/imfinzi-approved-in-the-us-in-first-and-only-immunotherapy-combination-for-patients-with-bcg-naive--,c4354951cision5373073Fri, 29 May 2026 06:04:24 GMTUS FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional datahttps://news.cision.com/se/astrazeneca/r/us-fda-decision-date-extended-for-serena-6-filing-of-camizestrant-to-enable-review-of-additional-dat,c4353585cision5370982Wed, 27 May 2026 06:04:50 GMTDatroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidateshttps://news.cision.com/se/astrazeneca/r/datroway-approved-in-the-us-as-first-trop2-directed-antibody-drug-conjugate-for-1st-line-treatment-o,c4352299cision5368707Fri, 22 May 2026 13:41:05 GMTEnhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumourshttps://news.cision.com/se/astrazeneca/r/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-previously-treated-her2-positiv,c4352200cision5368631Fri, 22 May 2026 12:17:25 GMTCamizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancerhttps://news.cision.com/se/astrazeneca/r/camizestrant-in-combination-with-a-cdk4-6-inhibitor-recommended-for-approval-in-the-eu-by-chmp-for-1,c4352185cision5368462Fri, 22 May 2026 11:24:28 GMTAstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026https://news.cision.com/se/astrazeneca/r/astrazeneca-to-showcase-phase-iii-data-in-liver--breast-and-bladder-cancers-and-potential-first-in-c,c4351872cision5368077Fri, 22 May 2026 06:06:26 GMTEnhertu approved in the US for two new indications for patients with HER2-positive early breast cancerhttps://news.cision.com/se/astrazeneca/r/enhertu-approved-in-the-us-for-two-new-indications-for-patients-with-her2-positive-early-breast-canc,c4349389cision5364211Mon, 18 May 2026 06:12:51 GMTBaxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertensionhttps://news.cision.com/se/astrazeneca/r/baxfendy-approved-in-the-us-as-the-first-and-only-aldosterone-synthase-inhibitor-treatment-for-adult,c4349381cision5364210Mon, 18 May 2026 06:07:19 GMTImfinzi + EV improves EFS & OS in bladder cancerhttps://news.cision.com/se/astrazeneca/r/imfinzi---ev-improves-efs---os-in-bladder-cancer,c4348675cision5363301Thu, 14 May 2026 06:05:47 GMTEneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trialhttps://news.cision.com/se/astrazeneca/r/eneboparatide-normalised-serum-calcium-and-achieved-independence-from-active-vitamin-d-and-oral-calc,c4347802cision5361969Tue, 12 May 2026 11:06:57 GMTTruqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancerhttps://news.cision.com/se/astrazeneca/r/truqap-recommended-by-fda-advisory-committee-for-pten-deficient-metastatic-hormone-sensitive-prostat,c4343754cision5355845Mon, 04 May 2026 06:18:52 GMTUpdate on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancerhttps://news.cision.com/se/astrazeneca/r/update-on-fda-advisory-committee-vote-on-camizestrant-in-combination-with-a-cdk4-6-inhibitor-for-adv,c4343747cision5355838Mon, 04 May 2026 06:07:24 GMTResultat för AstraZeneca: Första kvartalet 2026https://news.cision.com/se/astrazeneca/r/resultat-for-astrazeneca--forsta-kvartalet-2026,c4341856cision5353131Wed, 29 Apr 2026 06:00:46 GMTBreztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and olderhttps://news.cision.com/se/astrazeneca/r/breztri-approved-in-the-us-for-asthma-as-first-and-only-triple-therapy-for-patients-12-years-of-age-,c4341020cision5351703Tue, 28 Apr 2026 06:06:53 GMTSaphnelo approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosushttps://news.cision.com/se/astrazeneca/r/saphnelo-approved-in-the-us-for-subcutaneous-self-administration-as-a-new-autoinjector-for-the-treat,c4340349cision5350709Mon, 27 Apr 2026 06:06:50 GMTChange to AstraZeneca Board of Directorshttps://news.cision.com/se/astrazeneca/r/change-to-astrazeneca-board-of-directors,c4339024cision5348786Thu, 23 Apr 2026 06:42:53 GMTUltomiris demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with immunoglobulin A nephropathy in I CAN Phase III trialhttps://news.cision.com/se/astrazeneca/r/ultomiris-demonstrated-statistically-significant-and-clinically-meaningful-reduction-of-proteinuria-,c4337484cision5346521Tue, 21 Apr 2026 06:06:50 GMTTozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPDhttps://news.cision.com/se/astrazeneca/r/tozorakimab-met-primary-endpoint-in-phase-iii-miranda-trial-in-patients-with-copd,c4336861cision5345717Mon, 20 Apr 2026 06:06:45 GMTAlexion data at 2026 AAN Annual Meeting reflects industry-leading portfolio and commitment to enhancing care across rare diseaseshttps://news.cision.com/se/astrazeneca/r/alexion-data-at-2026-aan-annual-meeting-reflects-industry-leading-portfolio-and-commitment-to-enhanc,c4332955cision5340461Fri, 10 Apr 2026 06:07:02 GMT